Top

Published in:

01-12-2021 | Cytokines | Research

Head and neck squamous cell carcinoma cell lines have an immunomodulatory effect on macrophages independent of hypoxia and toll-like receptor 9

Authors: Tamiko Ishizu, Dominik Eichin, Artur Padzik, Sanni Tuominen, Reidar Grénman, Marko Salmi, Tove J. Grönroos, Johanna M. Tuomela

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

A low tissue oxygen level, < 1% O₂, is a typical characteristic inside of solid tumors in head and neck cancer (HNSCC) affecting a wide array of cell populations, such as macrophages. However, the mechanisms of how hypoxia influences macrophages are not yet fully elucidated. Our research aimed to study the effect of soluble mediators produced by hypoxic cancer cells on macrophage polarization. Furthermore, we studied the effect of a hypoxic microenvironment on the expression of tumorigenic toll-like receptor 9 (TLR9) and the consecutive macrophage polarization.

Methods

Conditioned media (CM_NOX or CM_HOX) from cell lines UT-SCC-8, UT-SCC-74A, FaDu, MDA-MB-231 and HaCat cultured under normoxic (21% O₂) and hypoxic (1% O₂) conditions were used to polarize human monocyte-derived macrophages. Macrophage polarization was measured by flow cytometry and the production of cytokine mRNA using Taqman qPCR. To study the role of TLR9 in macrophage polarization, the lentiviral CRISPR/Cas9 method was used to establish a stable FaDu^TLR9def clone.

Results

Our results demonstrate that the soluble mediators produced by the cancer cells under normoxia polarize macrophages towards a hybridized M1/M2a/M2c phenotype. Furthermore, the results suggest that hypoxia has a limited role in altering the array of cancer-produced soluble factors affecting macrophage polarization and cytokine production. Our data also indicates that increased expression of TLR9 due to hypoxia in malignant cells does not markedly influence the polarization of macrophages. TLR9 transcriptional response to hypoxia is dissimilar to a HIF1-α-regulated LDH-A. This may indicate a context-dependent expression of TLR9 under hypoxia.

Conclusions

HNSCC cell lines affect both macrophage activity (polarization) and functionality (cytokines), but with exception to iNOS expression, the effects appear independent of hypoxia and TLR9.

Available only for authorised users

Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature. 2013;496(7446):445–55. https://doi.org/10.1038/nature12034.CrossRefPubMedPubMedCentral

Tarique AA, Logan J, Thomas E, Holt PG, Sly PD, Fantino E. Phenotypic, functional, and plasticity features of classical and alternatively activated human macrophages. Am J Respir Cell Mol Biol. 2015;53(5):676–88. https://doi.org/10.1165/rcmb.2015-0012OC.CrossRefPubMed

Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014;6:1–13. https://doi.org/10.12703/P6-13.CrossRef

Quatromoni JG, Eruslanov E. Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. Am J Transl Res. 2012;4(4):376–89.PubMedPubMedCentral

Lurier EB, Dalton D, Dampier W, Raman P, Nassiri S, Ferraro NM, et al. Transcriptome analysis of IL-10-stimulated (M2c) macrophages by next-generation sequencing. Immunobiology. 2017;222(7):847–56. https://doi.org/10.1016/j.imbio.2017.02.006.CrossRefPubMedPubMedCentral

Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25(12):677–86. https://doi.org/10.1016/j.it.2004.09.015.CrossRefPubMed

Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117(1):175–84. https://doi.org/10.1172/JCI29881.CrossRefPubMedPubMedCentral

Vogel DY, Heijnen PD, Breur M, de Vries HE, Tool AT, Amor S, et al. Macrophages migrate in an activation-dependent manner to chemokines involved in neuroinflammation. J Neuroinflammation. 2014;11(1):23. https://doi.org/10.1186/1742-2094-11-23.CrossRefPubMedPubMedCentral

Sun Y, Tan TK, Yu X, Wang Y, Cao Q, Lu J, et al. Discrete functions of M 2a and M 2c macrophage subsets determine their relative efficacy in treating chronic kidney disease. Kidney Int. 2013;84(4):745–55. https://doi.org/10.1038/ki.2013.135.CrossRefPubMed

10.

Peng Q, Li M, Wang Z, Jiang M, Yan X, Lei S, et al. Polarization of tumor-associated macrophage is associated with tumor vascular normalization by endostatin. Thorac Cancer. 2013;4(3):295–305. https://doi.org/10.1111/1759-7714.12018.CrossRefPubMed

11.

Qian B-Z, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39–51. https://doi.org/10.1016/j.cell.2010.03.014.CrossRefPubMedPubMedCentral

12.

Paul S, Chhatar S, Mishra A, Lal G. Natural killer T cell activation increases iNOS+CD206- M1 macrophage and controls the growth of solid tumor. J Immunother Cancer. 2019;7(1):208. https://doi.org/10.1186/s40425-019-0697-7.CrossRefPubMedPubMedCentral

13.

Cheng H, Wang Z, Fu L, Xu T. Macrophage polarization in the development and progression of ovarian cancers: an overview. Front Oncol. 2019;9:1–11. https://doi.org/10.3389/fonc.2019.00421.CrossRef

14.

Sousa S, Brion R, Lintunen M, Kronqvist P, Sandholm J, Mönkkönen J, et al. Human breast cancer cells educate macrophages toward the M2 activation status. Breast Cancer Res. 2015;17(1):101. https://doi.org/10.1186/s13058-015-0621-0.CrossRefPubMedPubMedCentral

15.

Lisi L, Stigliano E, Lauriola L, Navarra P, Dello RC. Proinflammatory-activated glioma cells induce a switch in microglial polarization and activation status, from a predominant M2b phenotype to a mixture of M1 and M2a/B polarized cells. ASN Neuro. 2014;6(3):171–83. https://doi.org/10.1042/AN20130045.CrossRefPubMed

16.

Zhao X, Qu J, Sun Y, Wang J, Liu X, Wang F, et al. Prognostic significance of tumor-associated macrophages in breast cancer: a meta-analysis of the literature. Oncotarget. 2017;8:30576–86. https://doi.org/10.18632/oncotarget.15736.CrossRefPubMedPubMedCentral

17.

Koh MY, Spivak-Kroizman TR, Powis G. HIF-1 regulation: not so easy come, easy go. Trends Biochem Sci. 2008;33(11):526–34. https://doi.org/10.1016/j.tibs.2008.08.002.CrossRef

18.

Raggi F, Pelassa S, Pierobon D, Penco F, Gattorno M, Novelli F, et al. Regulation of Human Macrophage M1–M2 Polarization Balance by Hypoxia and the Triggering Receptor Expressed on Myeloid Cells-1. Front Immunol. 2017;8:1–18. https://doi.org/10.3389/fimmu.2017.01097.CrossRef

19.

Dehne N, Mora J, Namgaladze D, Weigert A, Brüne B. Cancer cell and macrophage cross-talk in the tumor microenvironment. Curr Opin Pharmacol. 2017;35:12–9. https://doi.org/10.1016/j.coph.2017.04.007.CrossRefPubMed

20.

Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, et al. Macrophage polarization in tumour progression. Semin Cancer Biol. 2008;18(5):349–55. https://doi.org/10.1016/j.semcancer.2008.03.004.CrossRefPubMed

21.

Väisänen M-R, Väisänen T, Jukkola-Vuorinen A, Vuopala KS, Desmond R, Selander KS, et al. Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors. Prostate. 2010;70(8):817–24. https://doi.org/10.1002/pros.21115.CrossRefPubMed

22.

Kauppila JH, Takala H, Selander KS, Lehenkari PP, Saarnio J, Karttunen TJ. Increased toll-like receptor 9 expression indicates adverse prognosis in oesophageal adenocarcinoma. Histopathology. 2011;59(4):643–9. https://doi.org/10.1111/j.1365-2559.2011.03991.x.CrossRefPubMed

23.

Tuomela J, Sandholm J, Karihtala P, Ilvesaro J, Vuopala KS, Kauppila JH, et al. Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer. Breast Cancer Res Treat. 2012;135(2):481–93. https://doi.org/10.1007/s10549-012-2181-7.CrossRefPubMed

24.

Sandholm JA, Tuomela JM, Kauppila JH, Harris KW, Graves D, Selander KS. Hypoxia regulates toll-like receptor-9 expression and invasive function in human brain cancer cells in vitro. Oncol Lett. 2014;8(1):266–74. https://doi.org/10.3892/ol.2014.2095.CrossRefPubMedPubMedCentral

25.

Pries R, Wollenberg B. Cytokines in head and neck cancer. Cytokine Growth Factor Rev. 2006;17(3):141–6. https://doi.org/10.1016/j.cytogfr.2006.02.001.CrossRefPubMed

26.

Mantegazza AR, Magalhaes JG, Amigorena S, Marks MS. Presentation of phagocytosed antigens by MHC class I and II. Traffic. 2013;14(2):135–52. https://doi.org/10.1111/tra.12026.CrossRefPubMed

27.

Zizzo G, Cohen PL. IL-17 stimulates differentiation of human anti-inflammatory macrophages and phagocytosis of apoptotic neutrophils in response to IL-10 and glucocorticoids. J Immunol. 2013;190(10):5237–46. https://doi.org/10.4049/jimmunol.1203017.CrossRefPubMed

28.

Bowdish DME, Loffredo MS, Mukhopadhyay S, Mantovani A, Gordon S. Macrophage receptors implicated in the “adaptive” form of innate immunity. Microbes Infect. 2007;9(14-15):1680–7. https://doi.org/10.1016/j.micinf.2007.09.002.CrossRefPubMed

29.

Kurahara H, Shinchi H, Mataki Y, Maemura K, Noma H, Kubo F, et al. Significance of M2-polarized tumor-associated macrophage in pancreatic Cancer. J Surg Res. 2011;167(2):e211–9. https://doi.org/10.1016/j.jss.2009.05.026.CrossRefPubMed

30.

Weber M, Büttner-herold M, Hyckel P, Moebius P, Distel L, Ries J, et al. Small oral squamous cell carcinomas with nodal lymphogenic metastasis show increased infiltration of M2 polarized macrophages - an immunohistochemical analysis. J Cranio-Maxillofacial Surg. 2014;42(7):1087–94. https://doi.org/10.1016/j.jcms.2014.01.035.CrossRef

31.

Gustafsson C, Mjösberg J, Matussek A, Geffers R, Matthiesen L, Berg G, et al. Gene expression profiling of human Decidual macrophages: evidence for immunosuppressive phenotype. PLoS One. 2008;3(4):e2078. https://doi.org/10.1371/journal.pone.0002078.CrossRefPubMedPubMedCentral

32.

Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, Mukundan L, et al. Macrophage-specific PPARγ controls alternative activation and improves insulin resistance. Nature. 2007;447(7148):1116–20. https://doi.org/10.1038/nature05894.CrossRefPubMedPubMedCentral

33.

Raes G, Brys L, Dahal BK, Brandt J, Grooten J, Brombacher F, et al. Macrophage galactose-type C-type lectins as novel markers for alternatively activated macrophages elicited by parasitic infections and allergic airway inflammation. J Leukoc Biol. 2005;77(3):321–7. https://doi.org/10.1189/jlb.0304212.CrossRefPubMed

34.

Azizi E, Carr AJ, Plitas G, Cornish AE, Konopacki C, Prabhakaran S, et al. Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment. Cell. 2018;174:1293–1308.e36. https://doi.org/10.1016/j.cell.2018.05.060.CrossRefPubMedPubMedCentral

35.

Orecchioni M, Ghosheh Y, Pramod AB, Ley K. Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS–) vs. Alternatively Activated Macrophages. Front Immunol. 2019;10:1–14. https://doi.org/10.3389/fimmu.2019.01084.CrossRef

36.

Szulzewsky F, Pelz A, Feng X, Synowitz M, Markovic D, Langmann T, et al. Glioma-associated microglia/macrophages display an expression profile Different from M1 and M2 polarization and highly express Gpnmb and Spp1. PLoS One. 2015;10(2):e0116644. https://doi.org/10.1371/journal.pone.0116644.CrossRefPubMedPubMedCentral

37.

Tuit S, Salvagno C, Kapellos TS, Hau CS, Seep L, Oestreich M, et al. Transcriptional Signature Derived from Murine Tumor-Associated Macrophages Correlates with Poor Outcome in Breast Cancer Patients. Cell Rep. 2019;29:1221–1235.e5. https://doi.org/10.1016/j.celrep.2019.09.067.CrossRefPubMedPubMedCentral

38.

Chen H-J, Li Yim AYF, Griffith GR, de Jonge WJ, Mannens MMAM, Ferrero E, et al. Meta-Analysis of in vitro-Differentiated Macrophages Identifies Transcriptomic Signatures That Classify Disease Macrophages in vivo. Front Immunol. 2019;10:1–15. https://doi.org/10.3389/fimmu.2019.02887.CrossRef

39.

Polanska H, Raudenska M, Gumulec J, Sztalmachova M, Adam V, Kizek R, et al. Clinical significance of head and neck squamous cell cancer biomarkers. Oral Oncol. 2014;50(3):168–77. https://doi.org/10.1016/j.oraloncology.2013.12.008.CrossRefPubMed

40.

Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, Smith CW, et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res. 1999;5(6):1369–79.PubMed

41.

Kesselring R, Thiel A, Pries R, Trenkle T, Wollenberg B. Human Th17 cells can be induced through head and neck cancer and have a functional impact on HNSCC development. Br J Cancer. 2010;103(8):1245–54. https://doi.org/10.1038/sj.bjc.6605891.CrossRefPubMedPubMedCentral

42.

Saccani A, Schioppa T, Porta C, Biswas SK, Nebuloni M, Vago L, et al. p50 nuclear factor-κB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res. 2006;66(23):11432–40. https://doi.org/10.1158/0008-5472.CAN-06-1867.CrossRefPubMed

43.

Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122(3):787–95. https://doi.org/10.1172/JCI59643.CrossRefPubMedPubMedCentral

44.

Gionfriddo G, Plastina P, Augimeri G, Catalano S, Giordano C, Barone I, et al. Modulating tumor-associated macrophage polarization by synthetic and natural PPARγ ligands as a potential target in breast Cancer. Cells. 2020;9(1):174. https://doi.org/10.3390/cells9010174.CrossRefPubMedCentral

45.

Van Ginderachter JA, Movahedi K, Van den Bossche J, De Baetselier P. Macrophages, PPARs, and Cancer. PPAR Res. 2008;2008:1–11. https://doi.org/10.1155/2008/169414.CrossRef

46.

Shu Y, Qin M, Song Y, Tang Q, Huang Y, Shen P, et al. M2 polarization of tumor-associated macrophages is dependent on integrin β 3 via peroxisome proliferator-activated receptor- γ up-regulation in breast cancer. Immunology. 2020;160(4):345–56. https://doi.org/10.1111/imm.13196.CrossRefPubMedPubMedCentral

47.

Chatterjee B, Saha P, Bose S, Shukla D, Chatterjee N, Kumar S, et al. MicroRNAs: as critical regulators of tumor- associated macrophages. Int J Mol Sci. 2020;21(19):7117. https://doi.org/10.3390/ijms21197117.CrossRefPubMedCentral

48.

Liu X, Chen Z, Yu J, Xia J, Zhou X. MicroRNA profiling and head and neck Cancer. Comp Funct Genomics. 2009;2009:1–11. https://doi.org/10.1155/2009/837514.CrossRef

49.

Benner B, Scarberry L, Suarez-Kelly LP, Duggan MC, Campbell AR, Smith E, et al. Generation of monocyte-derived tumor-associated macrophages using tumor-conditioned media provides a novel method to study tumor-associated macrophages in vitro. J Immunother Cancer. 2019;7(1):140. https://doi.org/10.1186/s40425-019-0622-0.CrossRefPubMedPubMedCentral

50.

Evans BJ, Haskard DO, Sempowksi G, Landis RC. Evolution of the macrophage CD163 phenotype and cytokine profiles in a human model of resolving inflammation. Int J Inflam. 2013;2013:1–9. https://doi.org/10.1155/2013/780502.CrossRef

51.

Moestrup S, Møller H. CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann Med. 2004;36(5):347–54. https://doi.org/10.1080/07853890410033171.CrossRefPubMed

52.

Evrard D, Szturz P, Tijeras-Raballand A, Astorgues-Xerri L, Abitbol C, Paradis V, et al. Macrophages in the microenvironment of head and neck cancer: potential targets for cancer therapy. Oral Oncol. November 2018;2019(88):29–38. https://doi.org/10.1016/j.oraloncology.2018.10.040.CrossRef

53.

Barros MHM, Hauck F, Dreyer JH, Kempkes B, Niedobitek G. Macrophage polarisation: an Immunohistochemical approach for identifying M1 and M2 macrophages. PLoS One. 2013;8(11):e80908. https://doi.org/10.1371/journal.pone.0080908.CrossRefPubMedPubMedCentral

54.

Movahedi K, Laoui D, Gysemans C, Baeten M, Stangé G, Van den Bossche J, et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010;70(14):5728–39. https://doi.org/10.1158/0008-5472.CAN-09-4672.CrossRefPubMed

55.

Wang B, Li Q, Qin L, Zhao S, Wang J, Chen X. Transition of tumor-associated macrophages from MHC class IIhi to MHC class IIlow mediates tumor progression in mice. BMC Immunol. 2011;12(1):43. https://doi.org/10.1186/1471-2172-12-43.CrossRefPubMedPubMedCentral

56.

Döcke W-D, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, et al. Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nat Med. 1997;3:3–8.CrossRef

57.

Lee K-S, Baek D-W, Kim K-H, Shin B-S, Lee D-H, Kim J-W, et al. IL-10-dependent down-regulation of MHC class II expression level on monocytes by peritoneal fluid from endometriosis patients. Int Immunopharmacol. 2005;5(12):1699–712. https://doi.org/10.1016/j.intimp.2005.05.004.CrossRefPubMed

58.

Escribese MM. Casas M, Corbí ángel L. influence of low oxygen tensions on macrophage polarization. Immunobiology. 2012;217(12):1233–40. https://doi.org/10.1016/j.imbio.2012.07.002.CrossRefPubMed

59.

Denko NC. Hypoxia, HIF and metabolism in the solid tumour. Nat Rev Cancer. 2008;8:705–13. https://doi.org/10.1038/nrc2468.CrossRefPubMed

60.

Colegio OR, Chu N-QQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014;513(7519):559–63. https://doi.org/10.1038/nature13490.CrossRefPubMedPubMedCentral

61.

Blouin CC, Pagé EL, Soucy GM, Richard DE. Hypoxic gene activation by lipopolysaccharide in macrophages: implication of hypoxia-inducible factor 1α. Blood. 2004;103(3):1124–30. https://doi.org/10.1182/blood-2003-07-2427.CrossRefPubMed

62.

Lee YS, Kim JW, Osborne O, Oh DY, Sasik R, Schenk S, et al. Increased adipocyte O2 consumption triggers HIF-1α, causing inflammation and insulin resistance in obesity. Cell. 2014;157(6):1339–52. https://doi.org/10.1016/j.cell.2014.05.012.CrossRefPubMedPubMedCentral

63.

Takeda N, O’Dea EL, Doedens A, Kim J-W, Weidemann A, Stockmann C, et al. Differential activation and antagonistic function of HIF- isoforms in macrophages are essential for NO homeostasis. Genes Dev. 2010;24(5):491–501. https://doi.org/10.1101/gad.1881410.CrossRefPubMedPubMedCentral

64.

Müller S, Kohanbash G, Liu SJ, Alvarado B, Carrera D, Bhaduri A, et al. Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment. Genome Biol. 2017;18(1):234. https://doi.org/10.1186/s13059-017-1362-4.CrossRefPubMedPubMedCentral

65.

Casella G, Garzetti L, Gatta AT, Finardi A, Maiorino C, Ruffini F, et al. IL4 induces IL6-producing M2 macrophages associated to inhibition of neuroinflammation in vitro and in vivo. J Neuroinflammation. 2016;13(1):1–10. https://doi.org/10.1186/s12974-016-0596-5.CrossRef

66.

Duffy SA, Taylor JMG, Terrell JE, Islam M, Li Y, Fowler KE, et al. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer. 2008;113(4):750–7. https://doi.org/10.1002/cncr.23615.CrossRefPubMed

67.

Riedel F, Zaiss I, Herzog D, Götte K, Naim R, Hörmann K. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma. Anticancer Res. 2005;25(4):2761–5. http://www.ncbi.nlm.nih.gov/pubmed/16080523.PubMed

68.

Costa NL, Valadares MC, Souza PPC, Mendonça EF, Oliveira JC, Silva TA, et al. Tumor-associated macrophages and the profile of inflammatory cytokines in oral squamous cell carcinoma. Oral Oncol. 2013;49(3):216–23. https://doi.org/10.1016/j.oraloncology.2012.09.012.CrossRefPubMed

69.

Pudla M, Srisatjaluk R, Utaisincharoen P. Induction of inducible nitric oxide synthase (iNOS) in Porphyromonas gingivalis LPS-treated mouse macrophage cell line (RAW264.7) requires Toll-like receptor 9. Inflamm Res. 2018;67:723–6. https://doi.org/10.1007/s00011-018-1168-1.CrossRefPubMed

70.

Mella M, Kauppila JH, Karihtala P, Lehenkari P, Jukkola-Vuorinen A, Soini Y, et al. Tumor infiltrating CD8 + T lymphocyte count is independent of tumor TLR9 status in treatment naïve triple negative breast cancer and renal cell carcinoma. Oncoimmunology. 2015;4(6):e1002726. https://doi.org/10.1080/2162402X.2014.1002726.CrossRefPubMedPubMedCentral

Title: Head and neck squamous cell carcinoma cell lines have an immunomodulatory effect on macrophages independent of hypoxia and toll-like receptor 9
Authors: Tamiko Ishizu
Dominik Eichin
Artur Padzik
Sanni Tuominen
Reidar Grénman
Marko Salmi
Tove J. Grönroos
Johanna M. Tuomela
Publication date: 01-12-2021
Publisher: BioMed Central
Keyword: Cytokines
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08357-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer

Associations of specific-age and decade recall body mass index trajectories with obesity-related cancer

Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019

One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre

CD47 expression and CD163+ macrophages correlated with prognosis of pancreatic neuroendocrine tumor

Significance of KDM6A mutation in bladder cancer immune escape

Keynote webinar | Spotlight on antibody–drug conjugates in cancer